{"id":"W2979430133","doi":"10.1182/blood.v106.11.447.447","title":"Results of Phase II Study of Lenalidomide (L) {Revlimid®} in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Lenalidomide; Medicine; Thalidomide; Internal medicine; Rituximab; Neutropenia; Gastroenterology; Bendamustine; Chronic lymphocytic leukemia; Pomalidomide; Refractory (planetary science); Multiple myeloma; Progressive disease; Phases of clinical research; Oncology; Immunology; Toxicity; Leukemia; Lymphoma; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006637552,0.0003231284,0.0009264946,0.0004447267,0.00006260338,0.000008430618,0.000352873,0.0001779921,0.000111596],"category_scores_gemma":[0.0006367497,0.0002298015,0.00009293839,0.0008011714,0.0002107398,0.0001760213,0.0001995335,0.000348593,0.00001766021],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.03340332,"about_ca_system_score_gemma":0.02802076,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001911762,"about_ca_topic_score_gemma":0.001229528,"domain_scores_codex":[0.996055,0.0001634991,0.001256541,0.0005998372,0.001323663,0.0006014749],"domain_scores_gemma":[0.9974939,0.0003004345,0.0004681426,0.001180456,0.0003287832,0.000228287],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4935891,0.2655083,0.03124486,0.00645507,0.006095399,0.003624731,0.03401255,0.007525475,0.02899591,0.00005153835,0.005471905,0.1174252],"study_design_scores_gemma":[0.9153573,0.04663624,0.01077143,0.001134451,0.000617307,0.00005530563,0.000496842,0.00271504,0.0210231,0.000002540685,0.0008451876,0.000345275],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9968428,0.0003902187,0.000001629249,0.00002678379,0.00004106652,0.00179303,0.00003811455,0.00004535366,0.0008210253],"genre_scores_gemma":[0.998293,0.00006842381,0.0002610544,0.00003614202,0.0001401929,0.00005776968,0.00004961549,0.00006556507,0.001028203],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4217682,"threshold_uncertainty_score":0.9774895,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01896449986318711,"score_gpt":0.2976178362957274,"score_spread":0.2786533364325403,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}